Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.05
ZBH's Cash-to-Debt is ranked lower than
97% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. ZBH: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
ZBH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.71 Max: 4.96
Current: 0.05
0.04
4.96
Equity-to-Asset 0.47
ZBH's Equity-to-Asset is ranked lower than
76% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ZBH: 0.47 )
Ranked among companies with meaningful Equity-to-Asset only.
ZBH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.03  Med: 0.66 Max: 0.84
Current: 0.47
0.03
0.84
Debt-to-Equity 0.79
ZBH's Debt-to-Equity is ranked lower than
86% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 0.30 vs. ZBH: 0.79 )
Ranked among companies with meaningful Debt-to-Equity only.
ZBH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02  Med: 0.26 Max: 17.37
Current: 0.79
0.02
17.37
Debt-to-EBITDA 5.23
ZBH's Debt-to-EBITDA is ranked lower than
82% of the 158 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. ZBH: 5.23 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ZBH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.32  Med: 1.2 Max: 9.98
Current: 5.23
0.32
9.98
Interest Coverage 4.07
ZBH's Interest Coverage is ranked lower than
92% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 66.37 vs. ZBH: 4.07 )
Ranked among companies with meaningful Interest Coverage only.
ZBH' s Interest Coverage Range Over the Past 10 Years
Min: 2.99  Med: 16.31 Max: 55.1
Current: 4.07
2.99
55.1
Piotroski F-Score: 6
Altman Z-Score: 2.29
Beneish M-Score: -2.41
WACC vs ROIC
10.41%
23.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 16.31
ZBH's Operating Margin % is ranked higher than
71% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. ZBH: 16.31 )
Ranked among companies with meaningful Operating Margin % only.
ZBH' s Operating Margin % Range Over the Past 10 Years
Min: 13.95  Med: 24.59 Max: 28.11
Current: 16.31
13.95
28.11
Net Margin % 21.34
ZBH's Net Margin % is ranked higher than
93% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. ZBH: 21.34 )
Ranked among companies with meaningful Net Margin % only.
ZBH' s Net Margin % Range Over the Past 10 Years
Min: 2.45  Med: 16.88 Max: 23.18
Current: 21.34
2.45
23.18
ROE % 14.95
ZBH's ROE % is ranked higher than
88% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. ZBH: 14.95 )
Ranked among companies with meaningful ROE % only.
ZBH' s ROE % Range Over the Past 10 Years
Min: 1.79  Med: 12.78 Max: 16.95
Current: 14.95
1.79
16.95
ROA % 6.42
ZBH's ROA % is ranked higher than
77% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: -0.26 vs. ZBH: 6.42 )
Ranked among companies with meaningful ROA % only.
ZBH' s ROA % Range Over the Past 10 Years
Min: 0.8  Med: 7.98 Max: 12.23
Current: 6.42
0.8
12.23
ROC (Joel Greenblatt) % 17.88
ZBH's ROC (Joel Greenblatt) % is ranked higher than
67% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 3.87 vs. ZBH: 17.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ZBH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 11.65  Med: 38.54 Max: 53.87
Current: 17.88
11.65
53.87
3-Year Revenue Growth Rate 12.20
ZBH's 3-Year Revenue Growth Rate is ranked higher than
72% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. ZBH: 12.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ZBH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.9  Med: 10.9 Max: 25.6
Current: 12.2
4.9
25.6
3-Year EBITDA Growth Rate 4.30
ZBH's 3-Year EBITDA Growth Rate is ranked lower than
53% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 7.50 vs. ZBH: 4.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ZBH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -9.2  Med: 6.5 Max: 43.6
Current: 4.3
-9.2
43.6
3-Year EPS without NRI Growth Rate 28.40
ZBH's 3-Year EPS without NRI Growth Rate is ranked higher than
77% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 7.80 vs. ZBH: 28.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ZBH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -43.6  Med: 8.9 Max: 41.7
Current: 28.4
-43.6
41.7
GuruFocus has detected 6 Warning Signs with Zimmer Biomet Holdings Inc ZBH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ZBH's 30-Y Financials

Financials (Next Earnings Date: 2018-10-31 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

ZBH Guru Trades in Q3 2017

George Soros 62,500 sh (New)
Barrow, Hanley, Mewhinney & Strauss 355 sh (New)
Larry Robbins 3,155,386 sh (+309.04%)
David Dreman 16,472 sh (+100.00%)
Joel Greenblatt 156,568 sh (+78.77%)
Mario Gabelli 485,919 sh (+55.32%)
Jana Partners 4,662,497 sh (+45.92%)
Robert Olstein 132,700 sh (+19.81%)
Steven Cohen 697,900 sh (+12.80%)
John Buckingham 46,108 sh (+3.78%)
Mairs and Power 1,096,486 sh (+1.67%)
Richard Pzena 2,023 sh (unchged)
First Eagle Investment 494 sh (unchged)
Pioneer Investments Sold Out
Andreas Halvorsen Sold Out
Jeff Auxier 86,544 sh (-0.08%)
John Rogers 1,057,463 sh (-0.43%)
PRIMECAP Management 661,100 sh (-0.68%)
Richard Snow 517,234 sh (-1.40%)
Ken Fisher 130,255 sh (-1.46%)
Jeremy Grantham 641,484 sh (-5.79%)
HOTCHKIS & WILEY 1,336,964 sh (-5.82%)
Private Capital 88,219 sh (-7.08%)
Scott Black 21,573 sh (-49.69%)
Paul Tudor Jones 4,150 sh (-72.20%)
Eaton Vance Worldwide Health Sciences Fund 182,716 sh (-9.65%)
» More
Q4 2017

ZBH Guru Trades in Q4 2017

Pioneer Investments 98,979 sh (New)
Paul Tudor Jones 23,029 sh (+454.92%)
George Soros 130,500 sh (+108.80%)
Joel Greenblatt 306,781 sh (+95.94%)
PRIMECAP Management 868,100 sh (+31.31%)
Richard Pzena 2,641 sh (+30.55%)
Robert Olstein 142,210 sh (+7.17%)
Mario Gabelli 516,794 sh (+6.35%)
Barrow, Hanley, Mewhinney & Strauss 377 sh (+6.20%)
Jeff Auxier 87,269 sh (+0.84%)
Mairs and Power 1,102,964 sh (+0.59%)
John Buckingham 46,305 sh (+0.43%)
Richard Snow 517,877 sh (+0.12%)
First Eagle Investment 494 sh (unchged)
Steven Cohen 100,000 sh (unchged)
Jeremy Grantham Sold Out
Larry Robbins Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
HOTCHKIS & WILEY 1,336,764 sh (-0.01%)
Scott Black 21,405 sh (-0.78%)
Private Capital 87,194 sh (-1.16%)
John Rogers 1,005,470 sh (-4.92%)
Ken Fisher 122,743 sh (-5.77%)
Jana Partners 3,854,500 sh (-17.33%)
Steven Cohen 512,686 sh (-26.54%)
David Dreman 363 sh (-97.80%)
» More
Q1 2018

ZBH Guru Trades in Q1 2018

Jim Simons 303,000 sh (New)
Caxton Associates 6,313 sh (New)
Richard Pzena 4,567 sh (+72.93%)
PRIMECAP Management 1,094,039 sh (+26.03%)
Mario Gabelli 563,967 sh (+9.13%)
Richard Snow 561,458 sh (+8.42%)
Pioneer Investments 102,073 sh (+3.13%)
John Buckingham 47,181 sh (+1.89%)
HOTCHKIS & WILEY 1,353,864 sh (+1.28%)
Mairs and Power 1,107,532 sh (+0.41%)
David Dreman 363 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Joel Greenblatt Sold Out
First Eagle Investment Sold Out
Barrow, Hanley, Mewhinney & Strauss Sold Out
Jeff Auxier 86,969 sh (-0.34%)
George Soros 128,000 sh (-1.92%)
Robert Olstein 137,540 sh (-3.28%)
Private Capital 84,287 sh (-3.33%)
John Rogers 955,511 sh (-4.97%)
Scott Black 19,843 sh (-7.30%)
Ken Fisher 107,036 sh (-12.80%)
Jana Partners 3,110,670 sh (-19.30%)
» More
Q2 2018

ZBH Guru Trades in Q2 2018

Vanguard Health Care Fund 2,447,976 sh (New)
Sarah Ketterer 1,187,863 sh (New)
Joel Greenblatt 77,071 sh (New)
Jim Simons 596,000 sh (+96.70%)
PRIMECAP Management 1,285,619 sh (+17.51%)
Robert Olstein 141,390 sh (+2.80%)
Richard Pzena 4,567 sh (unchged)
Steven Cohen 200,000 sh (unchged)
George Soros Sold Out
Caxton Associates Sold Out
Scott Black Sold Out
Jeff Auxier 86,654 sh (-0.36%)
John Buckingham 46,668 sh (-1.09%)
Mairs and Power 1,093,138 sh (-1.30%)
John Rogers 942,571 sh (-1.35%)
HOTCHKIS & WILEY 1,333,364 sh (-1.51%)
Private Capital 82,237 sh (-2.43%)
Richard Snow 545,354 sh (-2.87%)
Ken Fisher 103,159 sh (-3.62%)
Mario Gabelli 537,918 sh (-4.62%)
Jana Partners 2,849,125 sh (-8.41%)
Pioneer Investments 75,363 sh (-26.17%)
» More
» Details

Insider Trades

Latest Guru Trades with ZBH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-06-30 New Buy0.62%$105.18 - $117.46 $ 131.2417%2,447,976
HOTCHKIS & WILEY 2018-06-30 Reduce -1.51%0.01%$105.18 - $117.46 $ 131.2417%1,333,364
John Rogers 2018-06-30 Reduce -1.35%0.02%$105.18 - $117.46 $ 131.2417%942,571
Mario Gabelli 2018-06-30 Reduce -4.62%0.02%$105.18 - $117.46 $ 131.2417%537,918
Robert Olstein 2018-06-30 Add 2.80%0.06%$105.18 - $117.46 $ 131.2417%141,390
Ken Fisher 2018-06-30 Reduce -3.62%$105.18 - $117.46 $ 131.2417%103,159
Private Capital 2018-06-30 Reduce -2.43%0.04%$105.18 - $117.46 $ 131.2417%82,237
Joel Greenblatt 2018-06-30 New Buy0.12%$105.18 - $117.46 $ 131.2417%77,071
George Soros 2018-06-30 Sold Out 0.26%$105.18 - $117.46 $ 131.2417%0
HOTCHKIS & WILEY 2018-03-31 Add 1.28%0.01%$107.44 - $128.19 $ 131.2410%1,353,864
John Rogers 2018-03-31 Reduce -4.97%0.07%$107.44 - $128.19 $ 131.2410%955,511
Mario Gabelli 2018-03-31 Add 9.13%0.03%$107.44 - $128.19 $ 131.2410%563,967
Robert Olstein 2018-03-31 Reduce -3.28%0.07%$107.44 - $128.19 $ 131.2410%137,540
George Soros 2018-03-31 Reduce -1.92%0.01%$107.44 - $128.19 $ 131.2410%128,000
Ken Fisher 2018-03-31 Reduce -12.80%$107.44 - $128.19 $ 131.2410%107,036
Private Capital 2018-03-31 Reduce -3.33%0.06%$107.44 - $128.19 $ 131.2410%84,287
Richard Pzena 2018-03-31 Add 72.93%$107.44 - $128.19 $ 131.2410%4,567
Barrow, Hanley, Mewhinney & Strauss 2018-03-31 Sold Out $107.44 - $128.19 $ 131.2410%0
First Eagle Investment 2018-03-31 Sold Out $107.44 - $128.19 $ 131.2410%0
Joel Greenblatt 2018-03-31 Sold Out 0.54%$107.44 - $128.19 $ 131.2410%0
HOTCHKIS & WILEY 2017-12-31 Reduce -0.01%$108.72 - $124.46 $ 131.2413%1,336,764
John Rogers 2017-12-31 Reduce -4.92%0.07%$108.72 - $124.46 $ 131.2413%1,005,470
Mario Gabelli 2017-12-31 Add 6.35%0.02%$108.72 - $124.46 $ 131.2413%516,794
Joel Greenblatt 2017-12-31 Add 95.94%0.26%$108.72 - $124.46 $ 131.2413%306,781
Robert Olstein 2017-12-31 Add 7.17%0.15%$108.72 - $124.46 $ 131.2413%142,210
George Soros 2017-12-31 Add 108.80%0.23%$108.72 - $124.46 $ 131.2413%130,500
Ken Fisher 2017-12-31 Reduce -5.77%$108.72 - $124.46 $ 131.2413%122,743
Private Capital 2017-12-31 Reduce -1.16%0.02%$108.72 - $124.46 $ 131.2413%87,194
Richard Pzena 2017-12-31 Add 30.55%$108.72 - $124.46 $ 131.2413%2,641
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Add 6.20%$108.72 - $124.46 $ 131.2413%377
David Dreman 2017-12-31 Reduce -97.80%1.09%$108.72 - $124.46 $ 131.2413%363
HOTCHKIS & WILEY 2017-09-30 Reduce -5.82%0.04%$110.13 - $132.61 $ 131.2410%1,336,964
John Rogers 2017-09-30 Reduce -0.43%0.01%$110.13 - $132.61 $ 131.2410%1,057,463
Mario Gabelli 2017-09-30 Add 55.32%0.12%$110.13 - $132.61 $ 131.2410%485,919
Joel Greenblatt 2017-09-30 Add 78.77%0.12%$110.13 - $132.61 $ 131.2410%156,568
Robert Olstein 2017-09-30 Add 19.81%0.33%$110.13 - $132.61 $ 131.2410%132,700
Ken Fisher 2017-09-30 Reduce -1.46%$110.13 - $132.61 $ 131.2410%130,255
Private Capital 2017-09-30 Reduce -7.08%0.14%$110.13 - $132.61 $ 131.2410%88,219
George Soros 2017-09-30 New Buy0.22%$110.13 - $132.61 $ 131.2410%62,500
David Dreman 2017-09-30 Add 100.00%0.56%$110.13 - $132.61 $ 131.2410%16,472
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 New Buy$110.13 - $132.61 $ 131.2410%355
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare:NAS:ALGN, NYSE:EW, LSE:SN., NAS:ABMD, NYSE:TFX, XSWX:SOON, NYSE:VAR, SZSE:300003, OCSE:WDH, XPAR:DIM, ASX:COH, NYSE:BSX, LSE:CTEC, NZSE:FPH, NYSE:GMED, OCSE:AMBU B, NAS:IART, OCSE:GN, NAS:MASI, OSTO:EKTA B » details
Traded in other countries:ZIM.Germany, ZBH.Switzerland, 0QQD.UK,
Headquarter Location:USA
Zimmer Biomet Holdings Inc is a medical device company. It designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery under brands like NexGen, Persona, Zimmer, and Polaris.

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. It distributes and sells its products to hospitals and clinics worldwide under brand names like NexGen, Zimmer, VerSys, SoPlus, and Pulsavac.

Guru Investment Theses on Zimmer Biomet Holdings Inc

Jeff Auxier Comments on Zimmer Biomet Holdings - May 09, 2017

Zimmer Biomet (NYSE:ZBH) has a leading musculoskeletal portfolio and is the global market share leader in knees and hips. Zimmer is also predicting $2B in annual free cash flow by 2020. At year end the stock traded down to a steep discount to the market, an attractive 12 times earnings. The demographics favor hips and knees as the peak year is age 68—about the average age for baby boomers. According to the Pew Research Center, roughly 10,000 Americans turn 65 every day. Pain is a good motivator for action.

From Jeff Auxier (Trades, Portfolio)'s Auxier Asset Management first quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

John Rogers Comments on Zimmer Biomet Holdings - Jan 20, 2017

Other holdings underperformed. Orthopedic specialist Zimmer Biomet Holdings, Inc. (NYSE:ZBH) fell –20.44% after cutting guidance and admitting internal supply issues. Earnings were in-line, but revenue was negatively impacted by inventory for some high-end products. The company subsequently cut full-year earnings guidance from $8.00 per share to $ 7.95 per share. We view the supply problem as a short-term issue and believe the long-term future is bright for this best-in-class brand.

From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund fourth quarter 2016 commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about Zimmer Biomet Holdings Inc

Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2018
Zimmer Biomet Holdings to Present at Morgan Stanley 16th Annual Global Healthcare Conference
Sarah Ketterer’s Top 5 Buys of the 2nd Quarter Guru’s top buys include an ETF
Causeway Capital Management’s Sarah Ketterer (Trades, Portfolio) disclosed seven new positions when she released her second-quarter portfolio this week. Read more...
New Research Coverage Highlights EOG Resources, Zimmer Biomet, MGIC Investment, EPR Properties, Guess?, and Mednax — Consolidated Revenues, Company Growth, and Expectations for 2018
Vanguard Health Care Fund Establishes 6 New Positions Health care-focused fund releases 2nd-quarter portfolio
The Vanguard Health Care Fund (Trades, Portfolio) released its second-quarter portfolio earlier this week, listing six new positions. Read more...
Zimmer Biomet Appoints Maria Teresa (Tessa) Hilado and Syed Jafry to Board of Directors
Zimmer Biomet Holdings Announces Audio Webcast and Conference Call of Second Quarter 2018 Results
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2018
Zimmer Biomet to Present at Goldman Sachs 39th Annual Global Healthcare Conference
Zimmer Biomet Announces 510(k) Clearance for Zyston® Strut Open Titanium Interbody Spacer System

Ratios

vs
industry
vs
history
PE Ratio 15.87
ZBH's PE Ratio is ranked higher than
83% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 30.17 vs. ZBH: 15.87 )
Ranked among companies with meaningful PE Ratio only.
ZBH' s PE Ratio Range Over the Past 10 Years
Min: 9.07  Med: 19.77 Max: 397
Current: 15.87
9.07
397
Forward PE Ratio 16.45
ZBH's Forward PE Ratio is ranked higher than
90% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. ZBH: 16.45 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 15.87
ZBH's PE Ratio without NRI is ranked higher than
84% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 30.17 vs. ZBH: 15.87 )
Ranked among companies with meaningful PE Ratio without NRI only.
ZBH' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.07  Med: 19.77 Max: 397
Current: 15.87
9.07
397
Price-to-Owner-Earnings 9.59
ZBH's Price-to-Owner-Earnings is ranked higher than
91% of the 104 Companies
in the Global Medical Devices industry.

( Industry Median: 32.03 vs. ZBH: 9.59 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ZBH' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.67  Med: 19.44 Max: 110.83
Current: 9.59
7.67
110.83
PB Ratio 2.22
ZBH's PB Ratio is ranked higher than
66% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. ZBH: 2.22 )
Ranked among companies with meaningful PB Ratio only.
ZBH' s PB Ratio Range Over the Past 10 Years
Min: 1.26  Med: 2.15 Max: 3.38
Current: 2.22
1.26
3.38
PS Ratio 3.39
ZBH's PS Ratio is ranked higher than
50% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. ZBH: 3.39 )
Ranked among companies with meaningful PS Ratio only.
ZBH' s PS Ratio Range Over the Past 10 Years
Min: 1.82  Med: 3.05 Max: 4.82
Current: 3.39
1.82
4.82
Price-to-Free-Cash-Flow 20.26
ZBH's Price-to-Free-Cash-Flow is ranked higher than
65% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.44 vs. ZBH: 20.26 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ZBH' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.53  Med: 20.91 Max: 50.44
Current: 20.26
9.53
50.44
Price-to-Operating-Cash-Flow 15.32
ZBH's Price-to-Operating-Cash-Flow is ranked higher than
66% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 20.01 vs. ZBH: 15.32 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ZBH' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.88  Med: 13.22 Max: 25.25
Current: 15.32
6.88
25.25
EV-to-EBIT 46.94
ZBH's EV-to-EBIT is ranked lower than
79% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 24.76 vs. ZBH: 46.94 )
Ranked among companies with meaningful EV-to-EBIT only.
ZBH' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.6  Med: 14.6 Max: 80.8
Current: 46.94
6.6
80.8
EV-to-EBITDA 19.66
ZBH's EV-to-EBITDA is ranked lower than
51% of the 188 Companies
in the Global Medical Devices industry.

( Industry Median: 18.14 vs. ZBH: 19.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
ZBH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.5  Med: 11.2 Max: 34
Current: 19.66
5.5
34
EV-to-Revenue 4.51
ZBH's EV-to-Revenue is ranked lower than
58% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 3.73 vs. ZBH: 4.51 )
Ranked among companies with meaningful EV-to-Revenue only.
ZBH' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.9  Med: 3.5 Max: 6.4
Current: 4.51
1.9
6.4
PEG Ratio 11.36
ZBH's PEG Ratio is ranked lower than
83% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. ZBH: 11.36 )
Ranked among companies with meaningful PEG Ratio only.
ZBH' s PEG Ratio Range Over the Past 10 Years
Min: 1.02  Med: 3.39 Max: 233.22
Current: 11.36
1.02
233.22
Shiller PE Ratio 31.84
ZBH's Shiller PE Ratio is ranked higher than
72% of the 58 Companies
in the Global Medical Devices industry.

( Industry Median: 49.95 vs. ZBH: 31.84 )
Ranked among companies with meaningful Shiller PE Ratio only.
ZBH' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.13  Med: 26.21 Max: 37.11
Current: 31.84
15.13
37.11
Current Ratio 2.41
ZBH's Current Ratio is ranked lower than
81% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. ZBH: 2.41 )
Ranked among companies with meaningful Current Ratio only.
ZBH' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 2.78 Max: 13.11
Current: 2.41
1.14
13.11
Quick Ratio 1.25
ZBH's Quick Ratio is ranked lower than
87% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. ZBH: 1.25 )
Ranked among companies with meaningful Quick Ratio only.
ZBH' s Quick Ratio Range Over the Past 10 Years
Min: 0.71  Med: 1.77 Max: 11.78
Current: 1.25
0.71
11.78
Days Inventory 339.56
ZBH's Days Inventory is ranked lower than
86% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 143.61 vs. ZBH: 339.56 )
Ranked among companies with meaningful Days Inventory only.
ZBH' s Days Inventory Range Over the Past 10 Years
Min: 298.21  Med: 327.94 Max: 349.41
Current: 339.56
298.21
349.41
Days Sales Outstanding 61.56
ZBH's Days Sales Outstanding is ranked lower than
51% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 69.21 vs. ZBH: 61.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZBH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.56  Med: 70.48 Max: 88.03
Current: 61.56
61.56
88.03
Days Payable 57.66
ZBH's Days Payable is ranked lower than
51% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. ZBH: 57.66 )
Ranked among companies with meaningful Days Payable only.
ZBH' s Days Payable Range Over the Past 10 Years
Min: 42.16  Med: 52.73 Max: 68.22
Current: 57.66
42.16
68.22

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.73
ZBH's Dividend Yield % is ranked lower than
64% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 1.12 vs. ZBH: 0.73 )
Ranked among companies with meaningful Dividend Yield % only.
ZBH' s Dividend Yield % Range Over the Past 10 Years
Min: 0.28  Med: 0.83 Max: 1.1
Current: 0.73
0.28
1.1
Dividend Payout Ratio 0.12
ZBH's Dividend Payout Ratio is ranked higher than
94% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 0.32 vs. ZBH: 0.12 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ZBH' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.19 Max: 1.14
Current: 0.12
0.11
1.14
3-Year Dividend Growth Rate 2.90
ZBH's 3-Year Dividend Growth Rate is ranked lower than
64% of the 75 Companies
in the Global Medical Devices industry.

( Industry Median: 9.70 vs. ZBH: 2.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ZBH' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 6.9
Current: 2.9
0
6.9
Forward Dividend Yield % 0.73
ZBH's Forward Dividend Yield % is ranked lower than
75% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.48 vs. ZBH: 0.73 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.97
ZBH's 5-Year Yield-on-Cost % is ranked lower than
62% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.52 vs. ZBH: 0.97 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ZBH' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.37  Med: 1.1 Max: 1.46
Current: 0.97
0.37
1.46
3-Year Average Share Buyback Ratio -6.10
ZBH's 3-Year Average Share Buyback Ratio is ranked lower than
52% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: -5.70 vs. ZBH: -6.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ZBH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -8.3  Med: 1.6 Max: 7.2
Current: -6.1
-8.3
7.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.38
ZBH's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
81% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. ZBH: 1.38 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ZBH' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.59  Med: 1.15 Max: 2.24
Current: 1.38
0.59
2.24
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.48
ZBH's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
89% of the 27 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. ZBH: 1.48 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
ZBH' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.65  Med: 1.27 Max: 32.12
Current: 1.48
0.65
32.12
Price-to-Median-PS-Value 1.11
ZBH's Price-to-Median-PS-Value is ranked higher than
51% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. ZBH: 1.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ZBH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.66  Med: 1.16 Max: 3.03
Current: 1.11
0.66
3.03
Earnings Yield (Greenblatt) % 2.13
ZBH's Earnings Yield (Greenblatt) % is ranked higher than
59% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.74 vs. ZBH: 2.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ZBH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.2  Med: 6.8 Max: 15.2
Current: 2.13
1.2
15.2
Forward Rate of Return (Yacktman) % 7.80
ZBH's Forward Rate of Return (Yacktman) % is ranked higher than
50% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 6.60 vs. ZBH: 7.80 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ZBH' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.8  Med: 10.4 Max: 21.4
Current: 7.8
0.8
21.4

More Statistics

Revenue (TTM) (Mil) $7,917.60
EPS (TTM) $ 8.27
Beta1.44
Volatility20.32%
52-Week Range $104.28 - 134.55
Shares Outstanding (Mil)203.49

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 7,967 8,100 8,286 8,549
EBIT (Mil $) 1,521 2,082
EBITDA (Mil $) 2,571 3,127
EPS ($) 4.55 6.30 6.26 6.98
EPS without NRI ($) 4.55 6.30 6.26 6.98
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.19%
Dividends per Share ($) 0.96 0.96

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}